NYSE · Healthcare
CONMED Corp (CNMD)
As-reported financials and recent SEC filings for CONMED Corp, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$1.37B
Net income
$47.1M
Net margin
3.4%
Diluted EPS
$1.51
ROE
4.6%
P/E (TTM)
20.3×
Market cap
$1.08B
Debt / equity
0.8×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $1.37B | $1.31B | $1.24B | $1.05B | $1.01B |
| Gross profit | $750.5M | $733.0M | $676.2M | $571.2M | $568.0M |
| Operating income | $102.6M | $200.3M | $120.6M | $70.1M | $109.7M |
| Net income | $47.1M | $132.4M | $64.5M | $-80.6M | $62.5M |
| Diluted EPS | $1.51 | $4.25 | $2.04 | $-2.68 | $1.94 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
8-K2026-06-17
View on EDGAR →11-K2026-06-16
View on EDGAR →8-K2026-06-04
View on EDGAR →42026-06-03
View on EDGAR →42026-06-03
View on EDGAR →42026-06-03
View on EDGAR →42026-06-03
View on EDGAR →42026-06-03
View on EDGAR →Go deeper on CNMD
Search CONMED Corp’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.